Ferring, Aventis Reach $20M Deal In DDAVP Antitrust Suit

Law360, New York (August 4, 2011, 3:50 PM EDT) -- Ferring BV and Aventis Pharmaceuticals Inc. on Wednesday agreed to pay $20.25 million to settle with a proposed class of direct purchasers of DDAVP who claimed in a New York suit that the companies suppressed generic competition by fraudulently acquiring a patent for the diabetes drug.

Attorneys for the proposed class sought preliminary approval of a deal that calls for Ferring to shell out $16.75 million and Aventis to cough up $3.5 million to resolve allegations that the companies violated the Sherman Act.

The lawsuit, filed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.